nach oben

Medical Oncology

Erschienen in:

01.03.2014 | Original Paper

Tissue microarray analysis of X-linked inhibitor of apoptosis (XIAP) expression in breast cancer patients

verfasst von: Ying-Chun Xu, Qiang Liu, Jia-Qi Dai, Zhi-Qiang Yin, Lei Tang, Yue Ma, Xiao-Lin Lin, Hong-Xia Wang

Erschienen in: Medical Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

The goal of this study was to determine the diagnostic and prognostic potential of X-linked inhibitor of apoptosis (XIAP) expression in breast cancer. We analyzed a tissue microarray comprised of 100 breast cancer cases and 70 matched normal samples. Analysis of an online database, which included 2,977 patients, was also performed. There was a significant difference in cytoplasmic expression of XIAP (XIAP-C) between breast cancer tissue and matched normal (p < 0.001). Staining of XIAP-C was defined as negative (breast cancer 8.42 % vs. normal 30.91 %), slight (40.0 vs. 45.45 %), moderate (43.16 vs. 23.64 %), or high (8.42 vs. 0 %). High XIAP-C protein expression correlated with human epidermal growth factor receptor 2 (HER-2) status (p = 0.010) and with human p53 mutant-type (P53) status (p = 0.039). We found that XIAP expression did not correlate with disease-free survival (p = 0.706) and overall survival (p = 0.496) of breast cancer patients. An Internet-based system analysis confirmed our results. In the subgroup analysis, basal-like breast cancer patients with high XIAP levels in the tumor had a significantly increased risk of relapse; thus, the up-regulation of XIAP appeared to be predictive of poor relapse-free survival (p = 0.013). Kaplan–Meier curves also identified a significant correlation between distant metastasis-free survival and XIAP expression in patients with lymph-node-negative disease (p = 0.030). In summary, expression of XIAP-C was significantly higher in breast cancer compared to normal tissue. XIAP-C expression correlated with HER-2 status and may be considered a prognostic biomarker for basal-like breast cancer patients.

Yuan Y, Liao Y-M, Hsueh C-T, Mirshahidi HR. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol. 2011;4:16.PubMedCentralPubMedCrossRef

Firer MA, Gellerman G. Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol. 2012;5:70.PubMedCentralPubMedCrossRef

Chaoquan H, Huang L, Gest C, Xi X, Janin A, Soria C, Li H, He L. Opposite regulation by PI3 K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells. J Hematol Oncol. 2012;5:16.CrossRef

Chiang H-C, Nair SJ, Yeh I-T, Santillan AA, Hu Y, Elledge R, Li R. Association of radiotherapy with preferential depletion of luminal epithelial cells in a BRCA1 mutation carrier. Exp Hematol Oncol. 2012;1:31.PubMedCentralPubMedCrossRef

Vaux DL, Silke J. Mammalian mitochondrial IAP binding proteins. Biochem Biophys Res Commun. 2003;3:499–504.CrossRef

Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ, Pedersen IM, Kitada S, Scott FL, Bailly-Maitre B, Glinsky G, Scudiero D, Sausville E, Salvesen G, Nefzi A, Ostresh JM, Houghten RA, Reed JC. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell. 2004;1:25–35.CrossRef

Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997;6639:300–4.

Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998;8:2215–23.CrossRef

Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. 1999;18:5242–51.PubMedCrossRef

10.

Mohapatra S, Chu B, Zhao X, Pledger WJ. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res. 2005;65:7717–23.PubMed

11.

Cummins MJ, Kohli M, Rago C, Kinzler KW, Vogelstein B, Bunz F. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res. 2004;64:3006–8.PubMedCrossRef

12.

Berezovskaya O, Schimmer AD, Glinskii AB, Pinilla C, Hoffman RM, Reed JC, Glinsky GV. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res. 2005;65:2378–86.PubMedCrossRef

13.

Yang XH, Feng ZE, Yan M, Hanada S, Zuo H, Yang CZ, Han ZG, Guo W, Chen WT, Zhang P. XIAP is a predictor of cisplatin-based chemotherapy response and prognosis for patients with advanced head and neck cancer. PLoS One. 2012;3:e31601.CrossRef

14.

Chen X, Wang T, Yang D, Wang J, Li X, He Z, Chen F, Che X, Song X. Expression of the IAP protein family acts cooperatively to predict prognosis in human bladder cancer patients. Oncol Lett. 2013;4:1278–84.

15.

Shi YH, Ding WX, Zhou J, He JY, Xu Y, Gambotto AA, Rabinowich H, Fan J, Yin XM. Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology. 2008;2:497–507.CrossRef

16.

Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;3:725–31.CrossRef

17.

Zhang Y, Wang Y, Gao W, Zhang R, Han X, Jia M, Guan W. Transfer of siRNA against XIAP induces apoptosis and reduces tumor cells growth potential in human breast cancer in vitro and in vivo. Breast Cancer Res Treat. 2006;3:267–77.CrossRef

18.

Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, LaCasse EC. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res. 2003;9:2826–36.PubMed

19.

Lima RT, Martins LM, Guimarães JE, Sambade C, Vasconcelos MH. Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther. 2004;11:309–16.PubMedCrossRef

20.

Wang H, Huang M, Zhang DY, Zhang F. Global profiling of signaling networks: study of breast cancer stem cells and potential regulation. Oncologist. 2011;16:966–79.PubMedCrossRef

21.

Zhang FC, Song SL, Ma Y, Tang L, Xu YC, Wang HX. Effect of fibroblasts on breast cancer cell mammosphere formation and the regulation of stem cell-related gene expression. Int J Mol Med. 2011;3:365–71.

22.

Xu YC, Wang HX, Tang L, Ma Y, Zhang FC. A systematic review of vinorelbine for the treatment of breast cancer. Breast J. 2013;2:180–8.CrossRef

23.

Wang HX, Zhang FC, Ye F, Ma Y, David YZ. The effect of coptis chinensis on the signaling network in the squamous carcinoma cells. Front Biosci. 2011;3:326–40.CrossRef

24.

Zhang S, Ding F, Luo A, Chen A, Yu Z, Ren S, Liu Z, Zhang L. XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics. Cancer Biol Ther. 2007;6:6973–80.

25.

Bilim V, Yuuki K, Itoi T, Muto A, Kato T, Nagaoka A, Motoyama T, Tomita Y. Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis. Br J Cancer. 2008;98:941–9.PubMedCentralPubMedCrossRef

26.

Shi RX, Ong CN, Shen HM. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. Cancer Res. 2005;65:7815–23.PubMedCrossRef

27.

Sun H, Lu J, Liu L, Yi H, Qiu S, Yang CY, Deschamps JR, Wang S. Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. J Med Chem. 2010;17:6361–7.CrossRef

28.

Amantana A, Lon don CA, Iversen PL, Devi GR. X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther. 2004;3:699–707.PubMed

29.

Ming L, Tao S, Zhen-fei Y, Yan-qun NA. XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer. Chin Med J. 2007;6:469–73.

30.

Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem. 2002;46:44236–43.CrossRef

31.

Mizutani Y, Nakanishi H, Li YN, Matsubara H, Yamamoto K, Sato N, Shiraishi T, Nakamura T, Mikami K, Okihara K. Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol. 2007;30:919–25.PubMed

32.

Che Y, Ye F, Xu R, Qing H, Wang X, Yin F, Cui M, Burstein D, Jiang B, Zhang DY. Co-expression of XIAP and cyclinD1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma. Am J Pathol. 2012;5:1798–807.CrossRef

33.

Zhang Y, Zhu J, Tang Y, Li F, Zhou H, Peng B, Zhou C, Fu R. X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma. Diagn Pathol. 2011;6:49.PubMedCentralPubMedCrossRef

34.

Yang L, Cao Z, Yan H, Wood WC. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res. 2003;20:6815–24.

35.

Jaffer S, Orta L, Sunkara S, Sabo E, Burstein DE. Immunohistochemical detection of antiapoptotic protein X-linked inhibitor of apoptosis in mammary carcinoma. Hum Pathol. 2007;6:864–70.CrossRef

36.

Vitté-Mony I, Korneluk RG, Diaz-Mitoma F. Role of XIAP protein, a human member of the inhibitor of apoptosis (IAP) protein family, in phytohemagglutinin-induced apoptosis of human T cell lines. Apoptosis. 1997;2:501–9.PubMedCrossRef

37.

Tenev T, Zachariou A, Wilson R, Ditzel M, Meier P. IAPs are functionally non-equivalent and regulate effector caspases through distinct mechanisms. Nat Cell Biol. 2005;1:70–7.CrossRef

38.

Xiang G, Wen X, Wang H, Chen K, Liu H. Expression of X-linked inhibitor of apoptosis protein in human colorectal cancer and its correlation with prognosis. J Surg Oncol. 2009;8:708–12.

39.

Kim MA, Lee HE, Lee HS, Yang HK, Kim WH. Expression of apoptosis-related proteins and its clinical implication in surgically resected gastric carcinoma. Virchows Arch. 2011;5:503–10.CrossRef

40.

Aird KM, Ding X, Baras A, Wei J, Morse MA, Clay T, Lyerly HK, Devi GR. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. Mol Cancer Ther. 2008;1:38–47.CrossRef

Titel: Tissue microarray analysis of X-linked inhibitor of apoptosis (XIAP) expression in breast cancer patients
verfasst von: Ying-Chun Xu
Qiang Liu
Jia-Qi Dai
Zhi-Qiang Yin
Lei Tang
Yue Ma
Xiao-Lin Lin
Hong-Xia Wang
Publikationsdatum: 01.03.2014
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 3/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-013-0764-8

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Tissue microarray analysis of X-linked inhibitor of apoptosis (XIAP) expression in breast cancer patients

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

miR-200b as a prognostic factor targets multiple members of RAB family in glioma

VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma

Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia

Association analysis between the c.1804C>A genetic polymorphism of XRCC1 gene and risk of hepatocellular carcinoma in Chinese population

Haplotype analysis of the C677T and A1298C polymorphisms of MTHFR and susceptibility to chronic myeloid leukemia

Role of external beam radiotherapy in the treatment of relapsing meningioma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie